All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 51 points (-0.3%) at 16,416 as of Monday, Feb. 1, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,097 issues advancing vs. 1,872 declining with 189 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.3%. Top gainers within the sector include Intrexon ( XON), up 10.2%, Humana ( HUM), up 2.7%, HCA Holdings ( HCA), up 1.9%, Baxter International ( BAX), up 1.6% and Aetna ( AET), up 1.5%. On the negative front, top decliners within the sector include AbbVie ( ABBV), down 3.0%, Celgene ( CELG), down 2.1%, Bristol-Myers Squibb Company ( BMY), down 2.0%, Stryker Corporation ( SYK), down 1.5% and Abbott Laboratories ( ABT), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Alere ( ALR) is one of the companies pushing the Health Care sector higher today. As of noon trading, Alere is up $16.76 (45.0%) to $53.96 on heavy volume. Thus far, 19.9 million shares of Alere exchanged hands as compared to its average daily volume of 983,500 shares. The stock has ranged in price between $53.74-$54.11 after having opened the day at $54.11 as compared to the previous trading day's close of $37.20.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the United States and internationally. The company operates through Professional Diagnostics and Consumer Diagnostics segments. Alere has a market cap of $3.2 billion and is part of the health services industry. Shares are down 4.8% year-to-date as of the close of trading on Friday. Currently there are 4 analysts who rate Alere a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Alere as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full Alere Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Hologic ( HOLX) is up $1.20 (3.5%) to $35.14 on average volume. Thus far, 1.5 million shares of Hologic exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $33.85-$35.17 after having opened the day at $33.92 as compared to the previous trading day's close of $33.94.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. Hologic has a market cap of $9.4 billion and is part of the health services industry. Shares are down 12.3% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Hologic a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Hologic as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Hologic Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Edwards Lifesciences ( EW) is up $1.08 (1.4%) to $79.29 on light volume. Thus far, 474,266 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $77.65-$79.31 after having opened the day at $77.89 as compared to the previous trading day's close of $78.21.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $16.4 billion and is part of the health services industry. Shares are down 1.0% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Edwards Lifesciences Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).